Kisspeptin Research for IVF Oocyte Maturation Trigger
An evidence-based overview of research examining Kisspeptin in the context of ivf oocyte maturation trigger. This page synthesizes findings from peer-reviewed literature.
Research Summary
Kisspeptin-54 has been evaluated as an alternative to hCG for triggering oocyte maturation in IVF. Phase 2 RCTs at Imperial College London demonstrated 95% oocyte maturation rates with zero cases of OHSS in high-risk patients, compared to significant OHSS rates with conventional hCG triggering.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Kisspeptin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.